---
title: "CHINARES PHARMA's innovative drug \"Huasike\" has obtained exclusive rights for development, production, and commercialization in China"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/265111280.md"
description: "China Resources Pharmaceutical announced that it has signed an agreement with Langyu Group and Bioproject to obtain exclusive rights for the development, production, and commercialization of the innovative drug \"Huasike\" in China. This drug is the first innovative medication approved in the country for the treatment of narcolepsy, filling a clinical medication gap in this field, and has already received recommendations globally"
datetime: "2025-11-10T09:42:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265111280.md)
  - [en](https://longbridge.com/en/news/265111280.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265111280.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/265111280.md) | [繁體中文](https://longbridge.com/zh-HK/news/265111280.md)


# CHINARES PHARMA's innovative drug "Huasike" has obtained exclusive rights for development, production, and commercialization in China

China Resources Pharmaceutical (03320.HK) announced that its subsidiary China Resources Sanjiu (000999.SZ) has signed an agreement with Langyu Group and Bioproject, officially obtaining the exclusive rights for the development, production, and commercialization of the innovative drug "Huasu" (Tilidine Tablets) held by Langyu Group in China.

Huasu is the first innovative drug approved in China for the treatment of narcolepsy and is the first and currently the only non-controlled substance for this disease. It has received a Class I recommendation and Class A evidence for the symptoms of excessive daytime sleepiness, cataplexy, sleep hallucinations, and sleep paralysis in the "four syndromes." It is also recommended in guidelines in countries such as the United States and Europe, filling the gap in clinical medications for narcolepsy in China. Additionally, the indication for obstructive sleep apnea for Huasu has been approved in Europe

### 相关股票

- [CHINARES PHARMA (03320.HK)](https://longbridge.com/zh-CN/quote/03320.HK.md)

## 相关资讯与研究

- [China's detentions of Panama-flagged vessels raise concerns, Rubio says](https://longbridge.com/zh-CN/news/281541796.md)
- [Styland Subsidiary Commits US$3.4 Million to Alpha Perpetual Income Fund](https://longbridge.com/zh-CN/news/281380835.md)
- [CSPC Pharmaceutical, Alphamab Oncology's Breast Cancer Drug Study Meets Primary Endpoint](https://longbridge.com/zh-CN/news/281325910.md)
- [Grace Life-Tech Holdings FY revenue USD 13 million](https://longbridge.com/zh-CN/news/281224946.md)
- [Shin Hwa World logs FY revenue HK$966.9 mln](https://longbridge.com/zh-CN/news/281055310.md)